Welcome to our dedicated page for Ironwood news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood stock.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) is a biopharmaceutical company dedicated to creating innovative medicines that significantly improve the lives of patients. Founded in 1998, Ironwood specializes in gastrointestinal (GI) therapeutics and has a strong focus on developing and commercializing treatments for chronic conditions of the GI tract.
The company's flagship product is a medicine designed for adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This medicine, discovered and developed by Ironwood, is now fully commercialized and widely used to alleviate symptoms in patients, improving their quality of life.
Ironwood's research pipeline is robust, with multiple investigational medicines targeting both the upper and lower GI tract. The company leverages its expertise in gastrointestinal disorders and pharmacologic expertise in guanylate cyclases to develop new therapies that address unmet medical needs.
Beyond its core product, Ironwood is actively exploring new opportunities and expanding its portfolio through collaborative licenses, commercial agreements, and strategic acquisitions. These efforts aim to enhance the company's research, development, manufacturing, and marketing capabilities, thereby driving growth and innovation.
Recent achievements for Ironwood include the advancement of several clinical trials, promising data from ongoing research studies, and strategic partnerships aimed at enhancing product development and market reach. Financially, Ironwood continues to build value, achieving milestones that attract continued support from shareholders.
Ironwood Pharmaceuticals remains committed to its mission of making a difference for patients through the development of groundbreaking therapies. The company’s strong pipeline, dedicated team, and strategic initiatives position it as a leading player in the field of gastrointestinal therapeutics.
Ironwood Pharmaceuticals (Nasdaq: IRWD) has announced its upcoming second quarter 2024 investor update conference call and webcast, scheduled for Thursday, August 8, 2024, at 8:30 a.m. Eastern Time. Interested participants can join via phone or webcast. The call replay will be available until August 22, 2024, and the webcast archive will be accessible on Ironwood's website for one year after the call.
Key details:
- Conference call-in numbers: (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international)
- Conference ID and passcode: 2530602
- Webcast access: Investors section of www.ironwoodpharma.com
- Replay numbers: (800) 770-2030 (U.S. and Canada) or (609) 800-9909 (international)
Ironwood Pharmaceuticals (Nasdaq: IRWD) announces that CFO Sravan Emany will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:00 a.m. ET. The event will take place at the Marriott Marquis in New York City. A live webcast of the session will be available on the Investors section of Ironwood's website, and a replay will be accessible for one year post-event.
Ironwood Pharmaceuticals presented pivotal Phase III trial data at Digestive Disease Week® 2024, highlighting the efficacy and safety of the once-weekly subcutaneous apraglutide in adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF). The trial, called STARS, showed significant reductions in weekly parenteral support (PS) volume, with apraglutide patients achieving more days off PS and higher clinical responder rates compared to placebo. Notably, some patients achieved enteral autonomy. The study demonstrated apraglutide's well-tolerated safety profile, consistent with previous trials. Ironwood plans to submit a new drug application to the FDA based on these results, potentially offering a new treatment option for SBS-IF patients.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) reported positive Phase III results for apraglutide in adult patients with SBS-IF and explored SR GI aGVHD. LINZESS EUTRx demand grew by 10% YoY. FY 2024 guidance revised due to LINZESS gross-to-net change. Financial highlights include total revenue of $74.9 million, GAAP net loss of $4.2 million, and adjusted EBITDA of $12.8 million.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in The Citizens JMP Life Sciences Conference on May 13, 2024. The management will engage in a fireside chat at 10:00 a.m. ET at the New York Hilton Midtown. The event will be live streamed on the company's website. A replay will be available for 1 year.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will present new data on once-weekly apraglutide in short bowel syndrome with intestinal failure (SBS-IF) at the 2024 Digestive Disease Week®. The pivotal Phase III STARS study's findings and the STARS Nutrition Study will be highlighted, alongside additional posters focusing on linaclotide, irritable bowel syndrome, and functional constipation. Apraglutide data from the STARS trial aims to reduce parenteral support (PS) dependency in adult SBS-IF patients, with plans for a new drug application submission to the FDA.
FAQ
What is the current stock price of Ironwood (IRWD)?
What is the market cap of Ironwood (IRWD)?
What does Ironwood Pharmaceuticals specialize in?
What is Ironwood's flagship product?
When was Ironwood Pharmaceuticals founded?
What are some of Ironwood's recent achievements?
How does Ironwood plan to expand its research and development capabilities?
What areas does Ironwood's research pipeline target?
What other conditions, besides IBS-C and CIC, is Ironwood working on?
How does Ironwood build value for its shareholders?
Where is Ironwood Pharmaceuticals listed?
What is the company's mission?
